Literature DB >> 18771523

Glucocorticoids increase CD4CD25 cell percentage and Foxp3 expression in patients with multiple sclerosis.

M Braitch1, S Harikrishnan, R A Robins, C Nichols, A J Fahey, L Showe, C S Constantinescu.   

Abstract

OBJECTIVES: To determine whether percentages of CD4(+)CD25(high) T cells (a group of regulatory T cells, Treg) differ in patients with multiple sclerosis (MS) in relapse vs remission after glucocorticoid treatment and whether treatment for relapses changes Treg population and the expression of Foxp3, a key Treg-associated molecule.
MATERIALS AND METHODS: Peripheral blood mononuclear cells (PBMC) were obtained from 20 patients with MS during relapse, just before and 2 days after starting steroid treatment (i.v. methylprednisolone 1 g/day for 3 days) and then 6 weeks after treatment. CD4(+)CD25(hi) cells were analysed by using flow cytometry. Cytokines were measured by using an ELISA and Foxp3, CD3 and CD25 expression by using quantitative real-time PCR.
RESULTS: The percentage of CD4(+)CD25(hi) cells, plasma IL-10 and Foxp3/CD3 ratio increased 48 h after methylprednisolone initiation and returned to baseline values by 6 weeks post-treatment.
CONCLUSIONS: Results suggest that glucocorticoids increase Treg cell functional molecules and percentages. This may be a mechanism whereby steroids expedite recovery from MS relapses.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 18771523      PMCID: PMC4467559          DOI: 10.1111/j.1600-0404.2008.01090.x

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN: 0001-6314            Impact factor:   3.209


  31 in total

1.  Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells.

Authors:  Chandrashekhar Pasare; Ruslan Medzhitov
Journal:  Science       Date:  2003-01-16       Impact factor: 47.728

Review 2.  Toll-like receptors on regulatory T cells: expanding immune regulation.

Authors:  Roger P M Sutmuller; Mary E Morgan; Mihai G Netea; Oliver Grauer; Gosse J Adema
Journal:  Trends Immunol       Date:  2006-06-30       Impact factor: 16.687

Review 3.  Natural regulatory T cells: mechanisms of suppression.

Authors:  Makoto Miyara; Shimon Sakaguchi
Journal:  Trends Mol Med       Date:  2007-01-24       Impact factor: 11.951

4.  A novel role for the glucocorticoid receptor in the regulation of monocyte chemoattractant protein-1 mRNA stability.

Authors:  Latika Dhawan; Bin Liu; Burns C Blaxall; Mark B Taubman
Journal:  J Biol Chem       Date:  2007-02-02       Impact factor: 5.157

5.  Transient regulatory T-cells: a state attained by all activated human T-cells.

Authors:  Vinodh Pillai; Sterling B Ortega; C K Wang; Nitin J Karandikar
Journal:  Clin Immunol       Date:  2006-12-19       Impact factor: 3.969

6.  Effects of glucocorticoids on STAT4 activation in human T cells are stimulus-dependent.

Authors:  Angela J Fahey; R Adrian Robins; Karin B Kindle; David M Heery; Cris S Constantinescu
Journal:  J Leukoc Biol       Date:  2006-05-02       Impact factor: 4.962

7.  Avonex Combination Trial in relapsing--remitting MS: rationale, design and baseline data.

Authors:  J A Cohen; P A Calabresi; S Chakraborty; K R Edwards; T Eickenhorst; W L Felton; E Fisher; R J Fox; A D Goodman; C Hara-Cleaver; G J Hutton; P B Imrey; D M Ivancic; B F Mandell; J E Perryman; T F Scott; T T Skaramagas; H Zhang
Journal:  Mult Scler       Date:  2008-01-21       Impact factor: 6.312

8.  Glucocorticoid hormones upregulate interleukin 2 receptor alpha gene expression.

Authors:  M Lamas; E Sanz; L Martin-Parras; E Espel; P Sperisen; M Collins; A G Silva
Journal:  Cell Immunol       Date:  1993-10-15       Impact factor: 4.868

9.  Peripheral T cells are the therapeutic targets of glucocorticoids in experimental autoimmune encephalomyelitis.

Authors:  Simone Wüst; Jens van den Brandt; Denise Tischner; Anna Kleiman; Jan P Tuckermann; Ralf Gold; Fred Lühder; Holger M Reichardt
Journal:  J Immunol       Date:  2008-06-15       Impact factor: 5.422

10.  Classification and prediction of survival in patients with the leukemic phase of cutaneous T cell lymphoma.

Authors:  Laszlo Kari; Andrey Loboda; Michael Nebozhyn; Alain H Rook; Eric C Vonderheid; Calen Nichols; Dezso Virok; Celia Chang; Wen-Hwai Horng; James Johnston; Maria Wysocka; Michael K Showe; Louise C Showe
Journal:  J Exp Med       Date:  2003-06-02       Impact factor: 14.307

View more
  27 in total

1.  Autologous stromal vascular fraction therapy for rheumatoid arthritis: rationale and clinical safety.

Authors:  Jorge Paz Rodriguez; Michael P Murphy; Soonjun Hong; Marialaura Madrigal; Keith L March; Boris Minev; Robert J Harman; Chien-Shing Chen; Ruben Berrocal Timmons; Annette M Marleau; Neil H Riordan
Journal:  Int Arch Med       Date:  2012-02-08

2.  Central inflammation versus peripheral regulation in multiple sclerosis.

Authors:  L J Edwards; B Sharrack; A Ismail; H Tumani; C S Constantinescu
Journal:  J Neurol       Date:  2011-03-09       Impact factor: 4.849

3.  Neuromyelitis optica.

Authors:  William M Carroll; Kazuo Fujihara
Journal:  Curr Treat Options Neurol       Date:  2010-05       Impact factor: 3.598

4.  Intracerebral administration of CpG oligonucleotide for patients with recurrent glioblastoma: a phase II study.

Authors:  Alexandre Carpentier; Philippe Metellus; Renata Ursu; Sarah Zohar; Francois Lafitte; Maryline Barrié; Yuxia Meng; Margaretha Richard; Christophe Parizot; Florence Laigle-Donadey; Guy Gorochov; Dimitri Psimaras; Marc Sanson; Annick Tibi; Olivier Chinot; Antoine F Carpentier
Journal:  Neuro Oncol       Date:  2010-01-25       Impact factor: 12.300

5.  Foxp3+ regulatory T cells, Th17 effector cells, and cytokine environment in inflammatory bowel disease.

Authors:  Nicola Eastaff-Leung; Nicholas Mabarrack; Angela Barbour; Adrian Cummins; Simon Barry
Journal:  J Clin Immunol       Date:  2010-01       Impact factor: 8.317

6.  Genes differentially expressed by methylprednisolone in vivo in CD4 T lymphocytes from multiple sclerosis patients: potential biomarkers.

Authors:  C De Andres; M I García; H Goicoechea; M L Martínez-Ginés; J M García-Domínguez; M L Martín; F Romero-Delgado; A Benguría; M Sanjurjo; L A López-Fernández
Journal:  Pharmacogenomics J       Date:  2016-09-27       Impact factor: 3.550

7.  CD4+ T-cell reconstitution predicts survival outcomes after acute graft-versus-host-disease: a dual-center validation.

Authors:  Coco de Koning; Susan Prockop; Ichelle van Roessel; Nancy Kernan; Elizabeth Klein; Jurgen Langenhorst; Celina Szanto; Mirjam Belderbos; Marc Bierings; Farid Boulad; Dorine Bresters; Maria Cancio; Kevin Curran; Wouter Kollen; Richard O'Reilly; Andromachi Scaradavou; Barbara Spitzer; Birgitta Versluijs; Alwin Huitema; Caroline Lindemans; Stefan Nierkens; Jaap Jan Boelens
Journal:  Blood       Date:  2021-02-11       Impact factor: 22.113

8.  Impact of immunosuppressive drugs on the therapeutic efficacy of ex vivo expanded human regulatory T cells.

Authors:  Cristiano Scottà; Giorgia Fanelli; Sec Julie Hoong; Marco Romano; Estefania Nova Lamperti; Mitalee Sukthankar; Giuliana Guggino; Henrieta Fazekasova; Kulachelvy Ratnasothy; Pablo D Becker; Behdad Afzali; Robert I Lechler; Giovanna Lombardi
Journal:  Haematologica       Date:  2015-10-15       Impact factor: 9.941

9.  Cushing syndrome and glucocorticoids: T-cell lymphopenia, apoptosis, and rescue by IL-21.

Authors:  SuJin Hwang; Christina Tatsi; Hye Sun Kuehn; Julie E Niemela; Jennifer Stoddard; Yan Su; Maya Lodish; Gulbu Uzel; Rosanne Spolski; Warren J Leonard; Steven M Holland; Thomas A Fleisher; Constantine A Stratakis; Sergio D Rosenzweig
Journal:  J Allergy Clin Immunol       Date:  2021-06-02       Impact factor: 10.793

10.  Transcriptomic changes and potential regulatory mechanism of intrauterine human chorionic gonadotropin co-cultured with peripheral blood mononuclear cells infusion in mice with embryonic implantation dysfunction.

Authors:  Jiao Chen; Xuehan Zhao; Liangfei Ao; Tailang Yin; Jing Yang
Journal:  Ann Transl Med       Date:  2020-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.